Citadel Advisors’s Mesoblast MESO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$632K Buy
41,100
+10,000
+32% +$167K ﹤0.01% 8725
2025
Q4
$561K Sell
31,100
-35,000
-53% -$602K ﹤0.01% 8751
2025
Q3
$1.06M Buy
66,100
+2,700
+4% +$39.5K ﹤0.01% 7404
2025
Q2
$690K Sell
63,400
-19,300
-23% -$216K ﹤0.01% 7871
2025
Q1
$1.03M Sell
82,700
-33,950
-29% -$559K ﹤0.01% 6880
2024
Q4
$2.31M Buy
116,650
+64,750
+125% +$717K ﹤0.01% 5332
2024
Q3
$424K Sell
51,900
-1,600
-3% -$10.9K ﹤0.01% 8612
2024
Q2
$364K Buy
53,500
+29,200
+120% +$200K ﹤0.01% 8719
2024
Q1
$122K Buy
24,300
+15,850
+188% +$33.8K ﹤0.01% 11086
2023
Q4
$18.6K Sell
8,450
-1,750
-17% -$4.17K ﹤0.01% 12683
2023
Q3
$25.1K Sell
10,200
-11,600
-53% -$55.4K ﹤0.01% 12431
2023
Q2
$170K Sell
21,800
-12,300
-36% -$87.9K ﹤0.01% 10132
2023
Q1
$224K Buy
34,100
+23,800
+231% +$158K ﹤0.01% 9976
2022
Q4
$59.9K Sell
10,300
-1,350
-12% -$8.44K ﹤0.01% 11913
2022
Q3
$59K Sell
11,650
-7,850
-40% -$47.4K ﹤0.01% 11514
2022
Q2
$87K Buy
19,500
+14,250
+271% +$98.1K ﹤0.01% 11532
2022
Q1
$44K Sell
5,250
-600
-10% -$5.1K ﹤0.01% 12882
2021
Q4
$56K Sell
5,850
-10,650
-65% -$124K ﹤0.01% 13184
2021
Q3
$198K Sell
16,500
-12,000
-42% -$167K ﹤0.01% 11993
2021
Q2
$426K Buy
28,500
+12,250
+75% +$192K ﹤0.01% 10417
2021
Q1
$269K Sell
16,250
-20,200
-55% -$382K ﹤0.01% 11091
2020
Q4
$619K Sell
36,450
-17,050
-32% -$420K ﹤0.01% 7751
2020
Q3
$1.99M Buy
53,500
+21,000
+65% +$658K ﹤0.01% 4729
2020
Q2
$740K Buy
+32,500
New +$696K ﹤0.01% 6377

Other funds holding MESO

Citadel Advisors's MESO Position: Q1 2026 in Review

Citadel Advisors reduced its Mesoblast (MESO) stake by 35% in Q1 2026, selling an estimated $756K and leaving 85,959 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #7027.

Citadel Advisors first reported a position in MESO in Q3 2018 and has held it in 19 quarters since. The position peaked at $6.08M in Q1 2025. 69 funds tracked by Wall St. Rank hold MESO as of Q1 2026.

  • Citadel Advisors held 85,959 shares of Mesoblast worth $1.32M as of Q1 2026.
  • Citadel Advisors sold 45,429 Mesoblast shares in Q1 2026, an estimated $756K.
  • Mesoblast made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7027 holding.
  • Citadel Advisors first reported a position in Mesoblast in Q3 2018 and has held it in 19 quarters since.
  • Citadel Advisors's Mesoblast position peaked at $6.08M in Q1 2025.
  • 69 funds tracked by Wall St. Rank held Mesoblast as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.